NOVOCURE LIMITED

(NVCR)
  Report
Real-time Estimate Cboe BZX  -  11:18 2022-06-28 am EDT
74.00 USD   -0.92%
06/24NOVOCURE LIMITED(NASDAQGS : NVCR) added to Russell 2500 Index
CI
06/24NOVOCURE LIMITED(NASDAQGS : NVCR) added to Russell 2500 Growth Index
CI
06/21NovoCure Enrolls First Patient in Study of Tumor Treating Fields, Keytruda Combination to Treat Lung Cancer
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Piper Sandler Adjusts NovoCure's Price Target to $100 From $125, Reiterates Overweight Rating

05/13/2022 | 06:35am EDT


© MT Newswires 2022
All news about NOVOCURE LIMITED
06/24NOVOCURE LIMITED(NASDAQGS : NVCR) added to Russell 2500 Index
CI
06/24NOVOCURE LIMITED(NASDAQGS : NVCR) added to Russell 2500 Growth Index
CI
06/21NovoCure Enrolls First Patient in Study of Tumor Treating Fields, Keytruda Combination ..
MT
06/21Novocure Enrolls First Patient in KEYNOTE-B36, a Pilot Study of Tumor Treating Fields T..
BU
06/21Novocure Enrolls First Patient in KEYNOTE-B36, a Pilot Study of Tumor Treating Fields T..
CI
06/10NOVOCURE LTD : Change in Directors or Principal Officers, Amendments to Articles of Inc. o..
AQ
06/06HC Wainwright Initiates NovoCure at Buy, Sets Price Target at $115
MT
06/03Novocure Falls 5%, Zai Lab Rises 8%; Companies Report Study Results
DJ
06/03Zai Lab, Novocure's Phase 2 Study of Gastric Cancer Combination Therapy Meets Primary E..
MT
06/03NOVOCURE : Press Release of NovoCure Limited, dated June 3, 2022 - Form 8-K
PU
More news
Analyst Recommendations on NOVOCURE LIMITED
More recommendations
Financials (USD)
Sales 2022 552 M - -
Net income 2022 -62,6 M - -
Net Debt 2022 293 M - -
P/E ratio 2022 -129x
Yield 2022 -
Capitalization 7 812 M 7 812 M -
EV / Sales 2022 14,7x
EV / Sales 2023 13,6x
Nbr of Employees 1 167
Free-Float 86,5%
Chart NOVOCURE LIMITED
Duration : Period :
NovoCure Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVOCURE LIMITED
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 9
Last Close Price 74,69 $
Average target price 101,44 $
Spread / Average Target 35,8%
EPS Revisions
Managers and Directors
Asaf Danziger Chief Executive Officer & Director
Ashley Cordova Chief Financial Officer
William F. Doyle Executive Chairman
Uri Weinberg Chief Science Officer
Ely Benaim Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
NOVOCURE LIMITED0.69%7 907
MASIMO CORPORATION-52.66%7 693
SHOCKWAVE MEDICAL, INC.10.86%7 076
GETINGE AB-40.22%6 197
PENUMBRA, INC.-54.15%4 964
IRAY TECHNOLOGY COMPANY LIMITED-5.78%4 891